Multiple myeloma (MM) & related disorders

Similar documents
chronic leukemia lymphoma myeloma differentiated 14 September 1999 Transformed Pre- Ig Surface Surface Secreted B- ALL Macroglobulinemia Myeloma

Elevated Immunoglobulins and Paraproteins

This Infosheet explains what Monoclonal Gammopathy of Undetermined Significance (MGUS) is and how it is diagnosed and managed.

What do you do, with an M protein?

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL GENERAL FORMS AND GUIDELINES MYELOMA FORMS CHAPTER 16D REVISED: SEPTEMBER 2016

Diagnosis and Follow-up of Multiple Myeloma and Related Disorders: The role of the laboratory

Understanding MGUS and Smoldering Multiple Myeloma

Management of Multiple Myeloma: The Changing Paradigm

Freelite for Measurement of Urine-Free Light Chains in Monoclonal Gammopathies

Clinico hematological profile of multiple myeloma in tertiary care Hospital, Pune

Multiple Myeloma Patient Handbook

+ Serum Protein Electrophoresis with Immunofixation

Treatment options in Myeloma. BritModis myeloma for the elderly care specialist

Myeloma Bone Disease Current and Future Treatment. A Publication of The Bone and Cancer Foundation

Myeloma Primary Care. Dr R Lovell Feb 2015

Smouldering myeloma. Myeloma Infosheet Series. Other related conditions. Infoline:

Diagnosis and staging

A Study of Serum Protein Electrophoresis in Patients with Multiple Myeloma

Laboratories and the New IMWG Myeloma Guidelines

Measuring Myeloma in the LAB. BL Ferry Clinical Lead Sept 15 th 2014

Managing Patients with Multiple Myeloma: What the Specialty Pharmacist Needs to Know

Your Test Results. Understanding. Improving Lives Finding the Cure. Multiple Myeloma Cancer of the Bone Marrow

Strategies for Assessment of Immunotoxicology in Preclinical Drug Development

Preview of the Medifocus Guidebook on: Multiple Myeloma Updated February 23, 2018

Guidelines for the diagnosis and management of Myeloma within AngCN

To learn more about the MMRF, visit or call Accredited by: 2015 Multiple Myeloma Reseach Foundation

Urine Protein Electrophoresis and Immunoelectrophoresis Using Unconcentrated or Minimally Concentrated Urine Samples

Supplementary Appendix

Prevalence of Monoclonal Gammopathy of Undetermined Significance

Myeloma. Anne Grace, myeloma survivor. Support for this publication provided by

A Phase I/IIa Study of Human Anti-CD38 Antibody MOR03087 in Relapsed/Refractory Multiple Myeloma

UAMS. Forging the path to cure through exploration and discovery

Serum Free Light Chain Assay and κ/λ Ratio: Performance in Patients With Monoclonal Gammopathy-High False Negative Rate for κ/λ Ratio

Denosumab for the prevention of skeletal related events in patients with multiple myeloma first line

Transient Paraproteinemia: An Intriguing Immunological Anomaly

NICE guideline Published: 10 February 2016 nice.org.uk/guidance/ng35

Michael L. Astion, 3 Joseph Rank,1 Mark H. Wener, Paul Torvik, Joe B. Schneider,1 and Lawrence M. Kilhingsworth 2

CHAPTER 3 ANTIBODY STRUCTURE I

RESEARCH ARTICLE. Abstract. Introduction

THE PATH TO PRECISION MEDICINE IN MULTIPLE MYELOMA. themmrf.org

Concise Review. of the Disease and Treatment Options. Improving Lives Finding the Cure. Multiple Myeloma Cancer of the Bone Marrow

Treatment of Multiple Myeloma with Stem Cell Transplantation (SCT)

Accuracy of Serum IgM and IgA Monoclonal Protein Measurements by Densitometry

Immunotherapy in myeloma

Serum Free Light Chain Assay. Myeloma Infoguide Series

Corporate Medical Policy

PHYSICIAN OFFICE BILLING INFORMATION SHEET FOR IMLYGIC (talimogene laherparepvec)

Assessment of Monoclonal Gammopathies by Nephelometric Measurement of Individual Immunoglobulin / Ratios

FORENSIC SEROLOGY. Chapter PRENTICE HALL 2008 Pearson Education, Inc. Upper Saddle River, NJ 07458

Hot Topic. Disclosures. None

SERUM PROTEIN ELECTROPHORESIS

The Myeloma Guide Information for Patients and Caregivers

Myeloma Bone Disease

Iron Deficiency Anemia

Management of Multiple Myeloma: The Changing Paradigm

Immunological Techniques in Research and Clinical Medicine. Philip L. Cohen, M.D. Chief of Rheumatology, LKSOM 10 March 2016

Performance of the Sebia CAPILLARYS 2 for Detection and Immunotyping of Serum Monoclonal Paraproteins

1 Name. 1. (3 pts) What is apoptosis and how does it differ from necrosis? Which is more likely to trigger inflammation?

Anion Gap and Immunoglobulin Concentration

LYMPHOPROLIFERATIVE. ALL- Acute Lymphoblastic leukemia. Non Hodgkin Lymphomas. Hodgkin Lymphomas. CLL-Chronic Lymphocytic Leukemia

Basic Antibody Structure. Multiple myeloma = cancerous plasma cells Monomer = 150,000. Chapter 4. Immunoglobulin Structure and Function

Management of Multiple Myeloma: The Changing Paradigm

Blood Product Utilization

Maxillary pain is the first indication of the presence of multiple myeloma: A case report

Significance of Abnormal Protein Bands in Patients with Multiple Myeloma following Autologous Stem Cell Transplantation

Exam MOL3007 Functional Genomics

Session 1 Topics. Vascular Phase of Hemostasis. Coagulation Pathway. Action of Unfractionated Heparin. Laboratory Monitoring of Anticoagulant Therapy

Single Tube, Six-Color Flow Cytometric Analysis Is a Sensitive and Cost-Effective Technique for Assaying Clonal Plasma Cells

SPECIFIC PROTEIN MARKERS. Jenna Waldron 7 th June 2016

Managing Your Myeloma

Protein homology. Antigens & Antibodies I. Administrative issues:

XN Hematology Case Studies Every Picture Tells a Story

The Incidence and Significance of Pseudoparaproteins in a Community Hospital

Polyclonal versus monoclonal immunoglobulin-free light chains quantification

Serum protein electrophoresis: Italian survey 1986

The clinical utility of IPF in thrombocytopenia

Immunoglobulins: Structure and Function

Serology as a Diagnostic Technique

This talk will cover. Treatment for relapsed and/or refractory myeloma. What is relapsed myeloma and refractory myeloma. Treatment options for relapse

MEDICAL IMMUNOLOGY 544. Dr. George A. Gutman

Transgender Fundamentals for Health Care Practitioners Course # / 1.0 credit hours

not to be republished NCERT BIOTECHNOLOGY AND ITS APPLICATIONS CHAPTER BIOLOGY, EXEMPLAR PROBLEMS MULTIPLE-CHOICE QUESTIONS

Multiple myeloma is a malignancy

Dr Guy Pratt Consultant Haematologist, Heart of England NHS Foundation Trust. Natural course of myeloma. Some definitions. First relapse.

Do you think you'd be here today if you had not gone to M. D. Anderson?

Multiple Myeloma: Treatment Options for Newly Diagnosed Patients in Bangladesh Perspective

Laboratory Investigation of Challenging Cases. Laura A. Worfolk, Ph.D Scientific Director, Coagulation

Development and Challenges faced in Optimization of Sensitive Diagnostic Tests for Typhoid fever

Serum protein electrophoresis and immunofixation by a semiautomated electrophoresis system

ab Human TNFSF11 ELISA Kit (RANKL)

Laboratory Investigation of Challenging Cases. Laura A. Worfolk, Ph.D Scientific Director, Coagulation

Guideline on the clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular administration (SCIg/IMIg)

H-ferritin (Human) ELISA Kit

Antibody Structure. Antibodies

Antibody Structure supports Function

بسم هللا الرحمن الرحيم. Today we're going to talk about the generation of diversity of the receptors of the lymphocytes

Living With Myeloma Treatment and Side Effects Management

Four Experts Debate Aggressive Treatment Approaches and the Goal of Complete Response Recorded on April 19, 2014

LECTURE: 26 SIMPLE SEROLOGICAL LABORATORY TECHNIQUES LEARNING OBJECTIVES:

Transcription:

Multiple myeloma (MM) & related disorders

Plasma cell neoplasms Six major variants: (1) Multiple myeloma (2) Solitary plasmacytoma (3) Lymphoplasmacytic lymphoma They secrete a single complete or partial immunoglobulin can be secreted in serum, so called: monoclonal gammopathies mostly M protein (4) Heavy-chain disease (5) Primary amyloidosis (6) MGUS = monoclonal gammopathy of undetermined significance when we find M protein in normal elderly persons

MM, overview Mean age: 70 years More in males and Africans Principally involves the bone marrow Causes lytic lesions throughout the skeleton Median survival: 4-6 years

MM, overview cont d Production of M protein mainly of IgG type In 15-20%: only lambda or kappa light chains are produced excreted in urine called: Bence Jones proteins More commonly both light chains and complete immunoglobulins

Solitary plasmacytoma When it forms only a mass in bone or soft tissue Transform into multiple myeloma (bone marrow and blood involvement) over 5-10 years Modestly elevated M proteins are present in some cases at diagnosis Those of soft tissues: less likely to transform

MM, genetics

MM, bone lytic lesions The characteristic bone resorption results from the secretion of certain cytokines (e.g., IL-1β, tumor necrosis factor, IL-6) by myeloma cells These cytokines stimulate production of another cytokine called RANK-ligand, which stimulates the differentiation and absorptive activity of osteoclasts

MM, immunosuppression Although the plasma usually contains increased immunoglobulin owing to the presence of an M protein, the levels of functional antibodies often are profoundly depressed, leaving patients at high risk for bacterial infections

MM, renal dysfunction is a common, serious problem in myeloma Mostly due to obstructive proteinaceous casts, which often form in the distal convoluted tubules and the collecting ducts The casts consist mostly of Bence Jones proteins along with variable amounts of complete immunoglobulins, Tamm-Horsfall protein, and albumin Light chain deposition in the glomeruli or the interstitium either as amyloid or linear deposits also may contribute to renal dysfunction

MM, renal dysfunction, cont d Hypercalcemia, which may lead to dehydration and renal stones Frequent bouts of bacterial pyelonephritis, which stem in part from the hypogammaglobulinemia

MM, clinical manifestations

MM, diagnostic tests Serum and urine electrophoresis in 99% of cases, either a monoclonal complete immunoglobulin or a monoclonal free immunoglobulin light chain is present in the serum, the urine, or both sometimes: nonsecretory and only detected in plasma cells Bone marrow: increased plasma cells

MGUS M proteins are found in the serum of 1% to 3% of otherwise healthy persons older than age 50 years the most common plasma cell proliferation A precursor of MM 1% per year Similar chromosomal translocations Patients with MGUS have less than 3 g/dl of monoclonal protein in the serum and no Bence Jones proteinuria

Lymphoplasmacytic lymphoma Peak incidence is between 6 th and 7 th decade Secrete M proteins mostly IgM (macroglobulin) The tumor is a mixture of small B lymphocytes, plasmacytic lymphocytes and plasma cells An indolent lymphoma with common involvement of L.N.s, spleen & bone marrow

Lymphoplasmacytic lymphoma, cont d The high levels of IgM cause the blood to become viscous producing a syndrome called Waldenstrom macroglobulinemia Unlike multiple myeloma: -no free light chains or Bence Jones proteinuria -no lytic bone lesions -only rarely associated with amyloidosis

Lymphoplasmacytic lymphoma, Waldenstrom macroglobulinemia Visual impairment due to: retinal vascular changes Neurologic problems due to sluggish blood flow Bleeding interfering with clotting factors & platelets Cryoglobulinemia precipitation of IgM at low temperature will cause Raynaud phenomenon & cold urticaria